Progress in RNAi-mediated molecular therapy of acute and chronic myeloid leukemia

Molecular Therapy Nucleic Acids

Volumn 4, Issue 5, 2015, Pages e240-

  Landry, Breanne ^a   Valencia Serna, Juliana ^b   Gul Uludag, Hilal ^b   Jiang, Xiaoyan ^c,d   Janowska Wieczorek, Anna ^b   Brandwein, Joseph ^b   Uludag, Hasan ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Drug delivery; Leukemia; Molecular therapy; Nanoparticles; Nonviral vectors; RNAi; SiRNA

Indexed keywords

APTAMER; LIGAND; NANOPARTICLE; SMALL INTERFERING RNA;

ACUTE MYELOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; HUMAN; LEUKEMIA CELL; MOLECULAR THERAPY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; STEM CELL; THERAPY EFFECT;

EID: 84959194414     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2015.13     Document Type: Review

References (265)

1. National Cancer Institute Surveillance Research Program (2013). Fast Stats: An interactive tool for access to SEER cancer statistics. In: Surveillence RP (Ed.). .
2. Estey, EH (2013). Acute myeloid leukemia: 2013 update on risk-stratification and management. Am J Hematol 88: 318-327.
3. Stefanachi, A, Leonetti, F, Nicolotti, O, Catto, M, Pisani, L, Cellamare, S et al. (2012). New strategies in the chemotherapy of leukemia: eradicating cancer stem cells in chronic myeloid leukemia. Curr Cancer Drug Targets 12: 571-596.
4. Ferrara, F (2012). New agents for acute myeloid leukemia: is it time for targeted therapies? Expert Opin Investig Drugs 21: 179-189.
5. Baccarani, M, Cortes, J, Pane, F, Niederwieser, D, Saglio, G, Apperley, J et al.; European LeukemiaNet. (2009). Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27: 6041-6051.
6. Assouline, S and Lipton, JH (2011). Monitoring response and resistance to treatment in chronic myeloid leukemia. Curr Oncol 18: e71-e83.
7. O'Brien, SG, Guilhot, F, Larson, RA, Gathmann, I, Baccarani, M, Cervantes, F et al.; IRIS Investigators. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994-1004.
8. Ishikawa, F, Yoshida, S, Saito, Y, Hijikata, A, Kitamura, H, Tanaka, S et al. (2007). Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 25: 1315-1321.
9. Mikkola, HK, Radu, CG and Witte, ON (2010). Targeting leukemia stem cells. Nat Biotechnol 28: 237-238.
10. Iorns, E, Lord, CJ, Turner, N and Ashworth, A (2007). Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 6: 556-568.
11. Rossbach, M (2010). Small non-coding RNAs as novel therapeutics. Curr Mol Med 10: 361-368.
12. Sawyers, CL (2013). Perspective: combined forces. Nature 498: S7.
13. Weisberg, E, Manley, PW, Cowan-Jacob, SW, Hochhaus, A and Griffin, JD (2007). Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 7: 345-356.
14. Moore, AS, Kearns, PR, Knapper, S, Pearson, AD and Zwaan, CM (2013). Novel therapies for children with acute myeloid leukaemia. Leukemia 27: 1451-1460.
15. De Paula, D, Bentley, MV and Mahato, RI (2007). Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 13: 431-456.
16. Whitehead, KA, Langer, R and Anderson, DG (2009). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8: 129-138.
17. Guo, P (2010). The emerging field of RNA nanotechnology. Nat Nanotechnol 5: 833-842.
18. Fulda, S (2014). Inhibitor of apoptosis proteins in pediatric leukemia: molecular pathways and novel approaches to therapy. Front Oncol 4: 3.
19. Yoda, M, Kawamata, T, Paroo, Z, Ye, X, Iwasaki, S, Liu, Q et al. (2010). ATP-dependent human RISC assembly pathways. Nat Struct Mol Biol 17: 17-23.
20. Gioia, R, Leroy, C, Drullion, C, Lagarde, V, Etienne, G, Dulucq, S et al. (2011). Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells. Blood 118: 2211-2221.
21. Kosova, B, Tezcanli, B, Ekiz, HA, Cakir, Z, Selvi, N, Dalmizrak, A et al. (2010). Suppression of S TAT5A increases chemotherapeutic sensitivity in imatinib-resistant and imatinib-sensitive K562 cells. Leuk Lymphoma 51: 1895-1901.
22. Tanaka, N, Wang, YH, Shiseki, M, Takanashi, M and Motoji, T (2011). Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells. Leuk Res 35: 1219-1225.
23. Merkerova, M, Bruchova, H, Kracmarova, A, Klamova, H and Brdicka, R (2007). Bmi-1 over-expression plays a secondary role in chronic myeloid leukemia transformation. Leuk Lymphoma 48: 793-801.
24. Rangatia, J and Bonnet, D (2006). Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation. Leukemia 20: 68-76.
25. Scherr, M, Chaturvedi, A, Battmer, K, Dallmann, I, Schultheis, B, Ganser, A et al. (2006). Enhanced sensitivity to inhibition of SHP2, S TAT5, and Gab2 expression in chronic myeloid leukemia (CML). Blood 107: 3279-3287.
26. Arthanari, Y, Pluen, A, Rajendran, R, Aojula, H and Demonacos, C (2010). Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting BCR-ABL fusion gene in Chronic Myeloid Leukemia cells. J Control Release 145: 272-280.
27. Schepers, H, van Gosliga, D, Wierenga, AT, Eggen, BJ, Schuringa, JJ and Vellenga, E (2007). STAT5 is required for long-term maintenance of normal and leukemic human stem/progenitor cells. Blood 110: 2880-2888.
28. Tsai, BY, Suen, JL and Chiang, BL (2010). Lentiviral-mediated Foxp3 RNAi suppresses tumor growth of regulatory T cell-like leukemia in a murine tumor model. Gene Ther 17: 972-979.
29. Mintzer, MA and Simanek, EE (2009). Nonviral vectors for gene delivery. Chem Rev 109: 259-302.
30. Nel, AE, Mädler, L, Velegol, D, Xia, T, Hoek, EM, Somasundaran, P et al. (2009). Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 8: 543-557.
31. Janmey, PA and Kinnunen, PK (2006). Biophysical properties of lipids and dynamic membranes. Trends Cell Biol 16: 538-546.
32. Lodish, H, Berk, A, Kaiser, CA, Krieger, M and Bretscher, A (2007). Molecular Cell Biology. W H Freeman & Company, New York. pp. 1.
33. Brown, DA and London, E (2000). Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem 275: 17221-17224.
34. van Blitterswijk, WJ (1988). Structural basis and physiological control of membrane fluidity in normal and tumor cells. Subcell Biochem 13: 393-413.
35. Wang, X, Ren, J and Qu, X (2008). Targeted RNA interference of cyclin A2 mediated by functionalized single-walled carbon nanotubes induces proliferation arrest and apoptosis in chronic myelogenous leukemia K562 cells. ChemMedChem 3: 940-945.
36. Landry, B, Aliabadi, HM, Samuel, A, Gül-Uludag, H, Jiang, X, Kutsch, O et al. (2012). Effective non-viral delivery of siRNA to acute myeloid leukemia cells with lipid-substituted polyethylenimines. PLoS ONE 7: e44197.
37. Omedes Pujol, M, Coleman, DJ, Allen, CD, Heidenreich, O and Fulton, DA (2013). Determination of key structure-activity relationships in siRNA delivery with a mixed micelle system. J Control Release 172: 939-945.
38. Rothdiener, M, Müller, D, Castro, PG, Scholz, A, Schwemmlein, M, Fey, G et al. (2010). Targeted delivery of SiRNA to CD33-positive tumor cells with liposomal carrier systems. J Control Release 144: 251-258.
39. Hou, KK, Pan, H, Ratner, L, Schlesinger, PH and Wickline, SA (2013). Mechanisms of nanoparticle-mediated siRNA transfection by melittin-derived peptides. ACS Nano 7: 8605-8615.
40. Lee, YK, Kim, KS, Kim, JS, Baek, JE, Park, SI, Jeong, HY et al. (2010). Leukemia-specific siRNA delivery by immunonanoplexes consisting of anti-JL1 minibody conjugated to oligo-9 Arg-peptides. Mol Cells 29: 457-462.
41. Valencia-Serna, J, Gul-Uludag, H, Mahdipoor, P, Jiang, X and Uludag, H (2013). Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation. J Control Release 172: 495-503.
42. van Asbeck, AH, Beyerle, A, McNeill, H, Bovee-Geurts, PH, Lindberg, S, Verdurmen, WP et al. (2013). Molecular parameters of siRNA-cell penetrating peptide nanocomplexes for efficient cellular delivery. ACS Nano 7: 3797-3807.
43. Andaloussi, SE, Lehto, T, Mäger, I, Rosenthal-Aizman, K, Oprea, II, Simonson, OE et al. (2011). Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res 39: 3972-3987.
44. Eguchi, A, Meade, BR, Chang, YC, Fredrickson, CT, Willert, K, Puri, N et al. (2009). Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol 27: 567-571.
45. He, W, Bennett, MJ, Luistro, L, Carvajal, D, Nevins, T, Smith, M et al. (2014). Discovery of siRNA lipid nanoparticles to transfect suspension leukemia cells and provide in vivo delivery capability. Mol Ther 22: 359-370.
46. Yang, Z, Yu, B, Zhu, J, Huang, X, Xie, J, Xu, S et al. (2014). A microfluidic method to synthesize transferrin-lipid nanoparticles loaded with siRNA LOR-1284 for therapy of acute myeloid leukemia. Nanoscale 6: 9742-9751.
47. Mendonça, LS, Firmino, F, Moreira, JN, Pedroso de Lima, MC and Simões, S (2010). Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment. Bioconjug Chem 21: 157-168.
48. Aliabadi, HM, Landry, B, Sun, C, Tang, T and Uludag, H (2012). Supramolecular assemblies in functional siRNA delivery: where do we stand? Biomaterials 33: 2546-2569.
49. Wang, L, Zhang, WJ, Xiu, B, Ding, Y, Li, P, Ye, WD et al. (2014). Nanocomposite-siRNA approach for down-regulation of VEGF and its receptor in myeloid leukemia cells. Int J Biol Macromol 63: 49-55.
50. Howard, KA, Rahbek, UL, Liu, X, Damgaard, CK, Glud, SZ, Andersen, MØ et al. (2006). RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 14: 476-484.
51. Matokanovic, M, Barisic, K, Filipovic-Grcic, J and Maysinger, D (2013). Hsp70 silencing with siRNA in nanocarriers enhances cancer cell death induced by the inhibitor of Hsp90. Eur J Pharm Sci 50: 149-158.
52. Yin, H, Du, Y and Zhang, J (2009). Low molecular weight and oligomeric chitosans and their bioactivities. Curr Top Med Chem 9: 1546-1559.
53. Dominska, M and Dykxhoorn, DM (2010). Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci 123(Pt 8): 1183-1189.
54. Ferrati, S, Streiff, AK, Srinivasan, S, Alexander, JF, Bhargava, N, Peters, AM et al. (2011). Mass transport via cellular barriers and endocytosis. In: Prokop, A (Ed.). Intracellular Delivery: Fundamentals and Applications. Springer Netherlands: Dordrecht. pp. 3-55.
55. Karmali, PP and Simberg, D (2011). Interactions of nanoparticles with plasma proteins: implication on clearance and toxicity of drug delivery systems. Expert Opin Drug Deliv 8: 343-357.
56. Valencia Serna, J, Landry, B, Xiaoyan, J and Uludag, H (2014). Potential of siRNA therapy in chronic myeloid leukemia. In: Prokop A, Iwasaki Y and Harada A (Eds.). Intracellular Delivery II: Fundamentals and Applications. Springer Netherlands: Dordrecht. pp 435-473.
57. Lorenz, MR, Holzapfel, V, Musyanovych, A, Nothelfer, K, Walther, P, Frank, H et al. (2006). Uptake of functionalized, fluorescent-labeled polymeric particles in different cell lines and stem cells. Biomaterials 27: 2820-2828.
58. Labat-Moleur, F, Steffan, AM, Brisson, C, Perron, H, Feugeas, O, Furstenberger, P et al. (1996). An electron microscopy study into the mechanism of gene transfer with lipopolyamines. Gene Ther 3: 1010-1017.
59. Shahidi-Hamedani, N, Shier, WT, Moghadam Ariaee, F, Abnous, K and Ramezani, M (2013). Targeted gene delivery with noncovalent electrostatic conjugates of sgc-8c aptamer and polyethylenimine. J Gene Med 15: 261-269.
60. Huang, X, Schwind, S, Yu, B, Santhanam, R, Wang, H, Hoellerbauer, P et al. (2013). Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clin Cancer Res 19: 2355-2367.
61. Jin, Y, Liu, S, Yu, B, Golan, S, Koh, CG, Yang, J et al. (2010). Targeted delivery of antisense oligodeoxynucleotide by transferrin conjugated pH-sensitive lipopolyplex nanoparticles: a novel oligonucleotide-based therapeutic strategy in acute myeloid leukemia. Mol Pharm 7: 196-206.
62. Yang, X, Koh, CG, Liu, S, Pan, X, Santhanam, R, Yu, B et al. (2009). Transferrin receptor-targeted lipid nanoparticles for delivery of an antisense oligodeoxyribonucleotide against Bcl-2. Mol Pharm 6: 221-230.
63. Bellocq, NC, Pun, SH, Jensen, GS and Davis, ME (2003). Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem 14: 1122-1132.
64. Chiu, SJ, Liu, S, Perrotti, D, Marcucci, G and Lee, RJ (2006). Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J Control Release 112: 199-207.
65. Retnakumari, AP, Hanumanthu, PL, Malarvizhi, GL, Prabhu, R, Sidharthan, N, Thampi, MV et al. (2012). Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia. Mol Pharm 9: 3062-3078.
66. Fonseca, C, Moreira, JN, Ciudad, CJ, Pedroso de Lima, MC and Simões, S (2005). Targeting of sterically stabilised pH-sensitive liposomes to human T-leukaemia cells. Eur J Pharm Biopharm 59: 359-366.
67. Citro, G, Szczylik, C, Ginobbi, P, Zupi, G and Calabretta, B (1994). Inhibition of leukaemia cell proliferation by folic acid-polylysine-mediated introduction of c-myb antisense oligodeoxynucleotides into HL-60 cells. Br J Cancer 69: 463-467.
68. Citro, G, Perrotti, D, Cucco, C, D'Agnano, I, Sacchi, A, Zupi, G et al. (1992). Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides. Proc Natl Acad Sci USA 89: 7031-7035.
69. Zhou, P, Hatziieremia, S, Elliott, MA, Scobie, L, Crossan, C, Michie, AM et al. (2010). Uptake of synthetic Low Density Lipoprotein by leukemic stem cells - a potential stem cell targeted drug delivery strategy. J Control Release 148: 380-387.
70. Liu, M, Li, W, Larregieu, CA, Cheng, M, Yan, B, Chu, T et al. (2014). Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity. Mol Pharm 11: 2305-2312.
71. Vidal, M, Sainte-Marie, J, Philippot, JR and Bienvenue, A (1985). LDL-mediated targeting of liposomes to leukemic lymphocytes in vitro. EMBO J 4: 2461-2467.
72. Medina, OP, Söderlund, T, Laakkonen, LJ, Tuominen, EK, Koivunen, E and Kinnunen, PK (2001). Binding of novel peptide inhibitors of type IV collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro. Cancer Res 61: 3978-3985.
73. Zhang, Q, Hossain, DM, Nechaev, S, Kozlowska, A, Zhang, W, Liu, Y et al. (2013). TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood 121: 1304-1315.
74. Zhang, H, Luo, J, Li, Y, Henderson, PT, Wang, Y, Wachsmann-Hogiu, S et al. (2012). Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells. Nanomedicine 8: 1116-1124.
75. Singh, A, Dilnawaz, F and Sahoo, SK (2011). Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy. PLoS ONE 6: e26803.
76. Vodovozova, EL, Gayenko, GP, Razinkov, VI, Korchagina, EY, Bovin, NV and Molotkovsky, JG (1998). Saccharide-assisted delivery of cytotoxic liposomes to human malignant cells. Biochem Mol Biol Int 44: 543-553.
77. Luo, YL, Shiao, YS and Huang, YF (2011). Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy. ACS Nano 5: 7796-7804.
78. Taghdisi, SM, Lavaee, P, Ramezani, M and Abnous, K (2011). Reversible targeting and controlled release delivery of daunorubicin to cancer cells by aptamer-wrapped carbon nanotubes. Eur J Pharm Biopharm 77: 200-206.
79. Wu, C, Han, D, Chen, T, Peng, L, Zhu, G, You, M et al. (2013). Building a multifunctional aptamer-based DNA nanoassembly for targeted cancer therapy. J Am Chem Soc 135: 18644-18650.
80. Chen, J, Chen, S, Zhao, X, Kuznetsova, LV, Wong, SS and Ojima, I (2008). Functionalized single-walled carbon nanotubes as rationally designed vehicles for tumor-targeted drug delivery. J Am Chem Soc 130: 16778-16785.
81. Chen, MH, Soda, Y, Izawa, K, Kobayashi, S, Tani, K, Maruyama, K et al. (2013). A versatile drug delivery system using streptavidin-tagged pegylated liposomes and biotinylated biomaterials. Int J Pharm 454: 478-485.
82. Varshosaz, J, Hassanzadeh, F, Sadeghi Aliabadi, H, Nayebsadrian, M, Banitalebi, M and Rostami, M (2014). Synthesis and characterization of folate-targeted dextran/retinoic acid micelles for doxorubicin delivery in acute leukemia. Biomed Res Int 2014: 525684.
83. Pan, XQ, Zheng, X, Shi, G, Wang, H, Ratnam, M and Lee, RJ (2002). Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 100: 594-602.
84. Pan, XQ and Lee, RJ (2005). In vivo antitumor activity of folate receptor-targeted liposomal daunorubicin in a murine leukemia model. Anticancer Res 25(1A): 343-346.
85. Lu, Y, Wu, J, Wu, J, Gonit, M, Yang, X, Lee, A et al. (2007). Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells. Mol Pharm 4: 707-712.
86. Li, H, Lu, Y, Piao, L, Wu, J, Liu, S, Marcucci, G et al. (2010). Targeting human clonogenic acute myelogenous leukemia cells via folate conjugated liposomes combined with receptor modulation by all-trans retinoic acid. Int J Pharm 402: 57-63.
87. Shi, Y, Su, Z, Li, S, Chen, Y, Chen, X, Xiao, Y et al. (2013). Multistep targeted nano drug delivery system aiming at leukemic stem cells and minimal residual disease. Mol Pharm 10: 2479-2489.
88. Huxford, RC, Dekrafft, KE, Boyle, WS, Liu, D and Lin, W (2012). Lipid-Coated Nanoscale Coordination Polymers for Targeted Delivery of Antifolates to Cancer Cells. Chem Sci 3: 10.1039/C1SC00499A.
89. Wang, W, Li, W, Ou, L, Flick, E, Mark, P, Nesselmann, C et al. (2011). Polyethylenimine-mediated gene delivery into human bone marrow mesenchymal stem cells from patients. J Cell Mol Med 15: 1989-1998.
90. Kircheis, R, Kichler, A, Wallner, G, Kursa, M, Ogris, M, Felzmann, T et al. (1997). Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery. Gene Ther 4: 409-418.
91. Matthay, KK, Abai, AM, Cobb, S, Hong, K, Papahadjopoulos, D and Straubinger, RM (1989). Role of ligand in antibody-directed endocytosis of liposomes by human T-leukemia cells. Cancer Res 49: 4879-4886.
92. Simard, P and Leroux, JC (2010). In vivo evaluation of pH-sensitive polymer-based immunoliposomes targeting the CD33 antigen. Mol Pharm 7: 1098-1107.
93. Guillem, VM, Tormo, M, Revert, F, Benet, I, García-Conde, J, Crespo, A et al. (2002). Polyethyleneimine-based immunopolyplex for targeted gene transfer in human lymphoma cell lines. J Gene Med 4: 170-182.
94. Yu, B, Mao, Y, Bai, LY, Herman, SE, Wang, X, Ramanunni, A et al. (2013). Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia. Blood 121: 136-147.
95. Vedi, A and Ziegler, DS (2014). Antibody therapy for pediatric leukemia. Front Oncol 4: 82.
96. Kung Sutherland, MS, Walter, RB, Jeffrey, SC, Burke, PJ, Yu, C, Kostner, H et al. (2013). SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood 122: 1455-1463.
97. Carrion, C, de Madariaga, MA and Domingo, JC (2004). In vitro cytotoxic study of immunoliposomal doxorubicin targeted to human CD34(+) leukemic cells. Life Sci 75: 313-328.
98. McNeer, NA, Chin, JY, Schleifman, EB, Fields, RJ, Glazer, PM and Saltzman, WM (2011). Nanoparticles deliver triplex-forming PNAs for site-specific genomic recombination in CD34+ human hematopoietic progenitors. Mol Ther 19: 172-180.
99. Kubo, T, Yanagihara, K, Sato, Y, Nishimura, Y, Kondo, S and Seyama, T (2013). Gene-silencing potency of symmetric and asymmetric lipid-conjugated siRNAs and its correlation with dicer recognition. Bioconjug Chem 24: 2045-2057.
100. Petrova, NS, Chernikov, IV, Meschaninova, MI, Dovydenko, IS, Venyaminova, AG, Zenkova, MA et al. (2012). Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group. Nucleic Acids Res 40: 2330-2344.
101. Chen, Q, Butler, D, Querbes, W, Pandey, RK, Ge, P, Maier, MA et al. (2010). Lipophilic siRNAs mediate efficient gene silencing in oligodendrocytes with direct CNS delivery. J Control Release 144: 227-232.
102. Wolfrum, C, Shi, S, Jayaprakash, KN, Jayaraman, M, Wang, G, Pandey, RK et al. (2007). Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 25: 1149-1157.
103. Moschos, SA, Jones, SW, Perry, MM, Williams, AE, Erjefalt, JS, Turner, JJ et al. (2007). Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem 18: 1450-1459.
104. Majeti, R (2011). Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene 30: 1009-1019.
105. Snauwaert, S, Vandekerckhove, B and Kerre, T (2013). Can immunotherapy specifically target acute myeloid leukemic stem cells? Oncoimmunology 2: e22943.
106. Barth, BM, I Altinoglu, E, Shanmugavelandy, SS, Kaiser, JM, Crespo-Gonzalez, D, DiVittore, NA et al. (2011). Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia. ACS Nano 5: 5325-5337.
107. Bakker, AB, van den Oudenrijn, S, Bakker, AQ, Feller, N, van Meijer, M, Bia, JA et al. (2004). C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res 64: 8443-8450.
108. Rainaldi, G, Filippini, P, Ferrante, A, Indovina, PL and Santini, MT (2001). Fibronectin facilitates adhesion of K562 leukemic cells normally growing in suspension to cationic surfaces. J Biomed Mater Res 55: 104-113.
109. Moll, J, Khaldoyanidi, S, Sleeman, JP, Achtnich, M, Preuss, I, Ponta, H et al. (1998). Two different functions for CD44 proteins in human myelopoiesis. J Clin Invest 102: 1024-1034.
110. Sun, YH, Sun, YL, Ran, XH, Cui, JY, Zhang, HL and Chen, ZX (2013). [The influence of CD44 on the adhesive, migratory and infiltrative abilities of leukemia cells]. Zhonghua Xue Ye Xue Za Zhi 34: 60-63.
111. Hertweck, MK, Erdfelder, F and Kreuzer, KA (2011). CD44 in hematological neoplasias. Ann Hematol 90: 493-508.
112. Choi, KY, Saravanakumar, G, Park, JH and Park, K (2012). Hyaluronic acid-based nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer. Colloids Surf B Biointerfaces 99: 82-94.
113. Almalik, A, Day, PJ and Tirelli, N (2013). HA-coated chitosan nanoparticles for CD44-mediated nucleic acid delivery. Macromol Biosci 13: 1671-1680.
114. Mahor, S, Dash, BC, O'Connor, S and Pandit, A (2012). Mannosylated polyethyleneimine-hyaluronan nanohybrids for targeted gene delivery to macrophage-like cell lines. Bioconjug Chem 23: 1138-1148.
115. Unzueta, U, Céspedes, MV, Ferrer-Miralles, N, Casanova, I, Cedano, J, Corchero, JL et al. (2012). Intracellular CXCR4? cell targeting with T22-empowered protein-only nanoparticles. Int J Nanomedicine 7: 4533-4544.
116. Guo, P, You, JO, Yang, J, Jia, D, Moses, MA and Auguste, DT (2014). Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade. Mol Pharm 11: 755-765.
117. Sison, EA and Brown, P (2011). The bone marrow microenvironment and leukemia: biology and therapeutic targeting. Expert Rev Hematol 4: 271-283.
118. Landry, B, Gül-Uludag, H and Uludag, H. (2013). Lipid-polymer mediated siRNA therapy for silencing CXCR4 in acute myeloid leukemia. Mol Ther 21: S177-S178.
119. Gul-Uludag, H, Valencia-Serna, J, Kucharski, C, Marquez-Curtis, LA, Jiang, X, Larratt, L et al. (2014). Polymeric nanoparticle-mediated silencing of CD44 receptor in CD34+ acute myeloid leukemia cells. Leuk Res 38: 1299-1308.
120. Hossain, DM, Dos Santos, C, Zhang, Q, Kozlowska, A, Liu, H, Gao, C et al. (2014). Leukemia cell-targeted S TAT 3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood 123: 15-25.
121. Fazzina, R, Lombardini, L, Mezzanotte, L, Roda, A, Hrelia, P, Pession, A et al. (2012). Generation and characterization of bioluminescent xenograft mouse models of MLL-related acute leukemias and in vivo evaluation of luciferase-targeting siRNA nanoparticles. Int J Oncol 41: 621-628.
122. Wang, C, Sheng, G, Lu, J, Xie, L, Bai, S, Wang, Y et al. (2012). Effect of RNAi-induced down regulation of nuclear factor kappa-B p65 on acute monocytic leukemia THP-1 cells in vitro and vivo. Mol Cell Biochem 359: 125-133.
123. Wang, CM, Sheng, GY, Lu, J, Xie, L, Bai, ST, Xu, XJ et al. (2011). Effect of small interfering RNA targeting wild-type FLT3 in acute myeloid leukaemia cells in vitro and in vivo. J Int Med Res 39: 1661-1674.
124. Koldehoff, M and Elmaagacli, AH (2009). Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia. Methods Mol Biol 487: 451-466.
125. O'Brien, SM, Cunningham, CC, Golenkov, AK, Turkina, AG, Novick, SC and Rai, KR (2005). Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 23: 7697-7702.
126. Erba, HP, Sayar, H, Juckett, M, Lahn, M, Andre, V, Callies, S et al. (2013). Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). Invest New Drugs 31: 1023-1034.
127. Freireich, EJ, Gehan, EA, Rall, DP, Schmidt, LH and Skipper, HE (1966). Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50: 219-244.
128. Katragadda, L, Carter, BZ and Borthakur, G (2013). XIAP antisense therapy with AEG 35156 in acute myeloid leukemia. Expert Opin Investig Drugs 22: 663-670.
129. Cortes, J, Kantarjian, H, Ball, ED, Dipersio, J, Kolitz, JE, Fernandez, HF et al. (2012). Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia. Cancer 118: 418-427.
130. Callies, S, André, V, Patel, B, Waters, D, Francis, P, Burgess, M et al. (2011). Integrated analysis of preclinical data to support the design of the first in man study of LY2181308, a second generation antisense oligonucleotide. Br J Clin Pharmacol 71: 416-428.
131. Tauchi, T, Sumi, M, Nakajima, A, Sashida, G, Shimamoto, T and Ohyashiki, K (2003). BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. Clin Cancer Res 9: 4267-4273.
132. Raynaud, FI, Orr, RM, Goddard, PM, Lacey, HA, Lancashire, H, Judson, IR et al. (1997). Pharmacokinetics of G3139, a phosphorothioate oligodeoxynucleotide antisense to bcl-2, after intravenous administration or continuous subcutaneous infusion to mice. J Pharmacol Exp Ther 281: 420-427.
133. Novobrantseva, TI, Borodovsky, A, Wong, J, Klebanov, B, Zafari, M, Yucius, K et al. (2012). Systemic RNAi-mediated Gene Silencing in Nonhuman Primate and Rodent Myeloid Cells. Mol Ther Nucleic Acids 1: e4.
134. Leuschner, F, Dutta, P, Gorbatov, R, Novobrantseva, TI, Donahoe, JS, Courties, G et al. (2011). Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 29: 1005-1010.
135. Courties, G, Seiffart, V, Presumey, J, Escriou, V, Scherman, D, Zwerina, J et al. (2010). In vivo RNAi-mediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells. Blood 116: 3505-3516.
136. Courties, G, Baron, M, Presumey, J, Escriou, V, van Lent, P, Scherman, D et al. (2011). Cytosolic phospholipase A2a gene silencing in the myeloid lineage alters development of Th1 responses and reduces disease severity in collagen-induced arthritis. Arthritis Rheum 63: 681-690.
137. Shi, B, Keough, E, Matter, A, Leander, K, Young, S, Carlini, E et al. (2011). Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery. J Histochem Cytochem 59: 727-740.
138. Kim, SS, Peer, D, Kumar, P, Subramanya, S, Wu, H, Asthana, D et al. (2010). RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in B LT mice. Mol Ther 18: 370-376.
139. Majmudar, MD, Keliher, EJ, Heidt, T, Leuschner, F, Truelove, J, Sena, BF et al. (2013). Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice. Circulation 127: 2038-2046.
140. Tyner, JW, Walters, DK, Willis, SG, Luttropp, M, Oost, J, Loriaux, M et al. (2008). RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood 111: 2238-2245.
141. Tyner, JW, Deininger, MW, Loriaux, MM, Chang, BH, Gotlib, JR, Willis, SG et al. (2009). RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci USA 106: 8695-8700.
142. Wohlbold, L, van der Kuip, H, Miething, C, Vornlocher, HP, Knabbe, C, Duyster, J et al. (2003). Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 102: 2236-2239.
143. Koldehoff, M, Zakrzewski, JL, Beelen, DW and Elmaagacli, AH (2013). Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells. Cancer Gene Ther 20: 421-427.
144. Zuber, J, Shi, J, Wang, E, Rappaport, AR, Herrmann, H, Sison, EA et al. (2011). RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524-528.
145. Hahn, CK, Berchuck, JE, Ross, KN, Kakoza, RM, Clauser, K, Schinzel, AC et al. (2009). Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 16: 281-294.
146. Banerji, V, Frumm, SM, Ross, KN, Li, LS, Schinzel, AC, Hahn, CK et al. (2012). The intersection of genetic and chemical genomic screens identifies GSK-3a as a target in human acute myeloid leukemia. J Clin Invest 122: 935-947.
147. Wang, X, Song, Y, Ren, J and Qu, X (2009). Knocking-down cyclin A(2) by siRNA suppresses apoptosis and switches differentiation pathways in K562 cells upon administration with doxorubicin. PLoS ONE 4: e6665.
148. Randrianarison-Huetz, V, Laurent, B, Bardet, V, Blobe, GC, Huetz, F and Duménil, D (2010). Gfi-1B controls human erythroid and megakaryocytic differentiation by regulating TGF-beta signaling at the bipotent erythro-megakaryocytic progenitor stage. Blood 115: 2784-2795.
149. Zheng, H, Chen, Y, Chen, S, Niu, Y, Yang, L, Li, B et al. (2011). Expression and distribution of PPP2R5C gene in leukemia. J Hematol Oncol 4: 21.
150. Shen, Q, Liu, S, Chen, Y, Yang, L, Chen, S, Wu, X et al. (2013). Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation. J Hematol Oncol 6: 64.
151. Sansonetti, A, Bourcier, S, Durand, L, Chomienne, C, Smadja-Joffe, F and Robert-Lézénès, J (2012). CD44 activation enhances acute monoblastic leukemia cell survival via Mcl-1 upregulation. Leuk Res 36: 358-362.
152. Kasper, S, Breitenbuecher, F, Heidel, F, Hoffarth, S, Markova, B, Schuler, M et al. (2012). Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies. Blood Cancer J 2: e60.
153. Wang, R, Xia, L, Gabrilove, J, Waxman, S and Jing, Y (2013). Downregulation of Mcl-1 through GSK-3β activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells. Leukemia 27: 315-324.
154. Konopleva, M, Tsao, T, Estrov, Z, Lee, RM, Wang, RY, Jackson, CE et al. (2004). The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res 64: 7927-7935.
155. Rao, J, Xu, DR, Zheng, FM, Long, ZJ, Huang, SS, Wu, X et al. (2011). Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells. J Transl Med 9: 71.
156. Cluzeau, T, Robert, G, Mounier, N, Karsenti, JM, Dufies, M, Puissant, A et al. (2012). BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients. Oncotarget 3: 490-501.
157. Bogenberger, JM, Kornblau, SM, Pierceall, WE, Lena, R, Chow, D, Shi, CX et al. (2014). BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia 28: 1657-1665.
158. McLornan, D, Hay, J, McLaughlin, K, Holohan, C, Burnett, AK, Hills, RK et al. (2013). Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia. Br J Haematol 160: 188-198.
159. Schepers, H, Geugien, M, van der Toorn, M, Bryantsev, AL, Kampinga, HH, Eggen, BJ et al. (2005). HSP27 protects AML cells against VP-16-induced apoptosis through modulation of p38 and c-Jun. Exp Hematol 33: 660-670.
160. Karami, H, Baradaran, B, Esfahani, A, Estiar, MA, Naghavi-Behzad, M, Sakhinia, M et al. (2013). siRNA-mediated silencing of survivin inhibits proliferation and enhances etoposide chemosensitivity in acute myeloid leukemia cells. Asian Pac J Cancer Prev 14: 7719-7724.
161. Porter, CC, Kim, J, Fosmire, S, Gearheart, CM, van Linden, A, Baturin, D et al. (2012). Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. Leukemia 26: 1266-1276.
162. Tibes, R, Bogenberger, JM, Chaudhuri, L, Hagelstrom, RT, Chow, D, Buechel, ME et al. (2012). RNAi screening of the kinome with cytarabine in leukemias. Blood 119: 2863-2872.
163. Balusu, R, Fiskus, W, Rao, R, Chong, DG, Nalluri, S, Mudunuru, U et al. (2011). Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood 118: 3096-3106.
164. Nishioka, C, Ikezoe, T, Yang, J, Komatsu, N, Koeffler, HP and Yokoyama, A (2009). Blockade of MEK signaling potentiates 5-Aza-2'-deoxycytidine-induced apoptosis and upregulation of p21(waf1) in acute myelogenous leukemia cells. Int J Cancer 125: 1168-1176.
165. Altman, JK, Glaser, H, Sassano, A, Joshi, S, Ueda, T, Watanabe-Fukunaga, R et al. (2010). Negative regulatory effects of Mnk kinases in the generation of chemotherapy-induced antileukemic responses. Mol Pharmacol 78: 778-784.
166. Nishioka, C, Ikezoe, T, Yang, J and Yokoyama, A (2010). Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1. Apoptosis 15: 795-804.
167. Ma, H, Ji, HY and Won, SL (2014). [Detection of citrus greening based on Vis-NIR spectroscopy and spectral feature analysis]. Guang Pu Xue Yu Guang Pu Fen Xi 34: 2713-2718.
168. Powell, JA, Thomas, D, Barry, EF, Kok, CH, McClure, BJ, Tsykin, A et al. (2009). Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood 114: 4859-4870.
169. Man, CH, Lam, SS, Sun, MK, Chow, HC, Gill, H, Kwong, YL et al. (2014). A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML. Blood 123: 2530-2539.
170. Seedhouse, CH, Mills, KI, Ahluwalia, S, Grundy, M, Shang, S, Burnett, AK et al. (2014). Distinct poor prognostic subgroups of acute myeloid leukaemia, FLT3-ITD and P-glycoprotein-positive, have contrasting levels of FOXO1. Leuk Res 38: 131-137.
171. Recher, C, Ysebaert, L, Beyne-Rauzy, O, Mansat-De Mas, V, Ruidavets, JB, Cariven, P et al. (2004). Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis. Cancer Res 64: 3191-3197.
172. De Toni, F, Racaud-Sultan, C, Chicanne, G, Mas, VM, Cariven, C, Mesange, F et al. (2006). A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia. Oncogene 25: 3113-3122.
173. Miyazaki, T, Kirino, Y, Takeno, M, Samukawa, S, Hama, M, Tanaka, M et al. (2010). Expression of heme oxygenase-1 in human leukemic cells and its regulation by transcriptional repressor Bach1. Cancer Sci 101: 1409-1416.
174. Mahon, FX, Hayette, S, Lagarde, V, Belloc, F, Turcq, B, Nicolini, F et al. (2008). Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression. Cancer Res 68: 9809-9816.
175. Baran, Y, Bielawski, J, Gunduz, U and Ogretmen, B (2011). Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation. J Cancer Res Clin Oncol 137: 1535-1544.
176. Zhang, YY, Xie, KM, Yang, GQ, Mu, HJ, Yin, Y, Zhang, B et al. (2011). The effect of glucosylceramide synthase on P-glycoprotein function in K562/AO2 leukemia drug-resistance cell line. Int J Hematol 93: 361-367.
177. Kim, HY, Oh, YS, Song, IC, Kim, SW, Lee, HJ, Yun, HJ et al. (2013). Endogenous stromal cell-derived factor-1 (CXCL12) supports autonomous growth of acute myeloid leukemia cells. Leuk Res 37: 566-572.
178. Yamakawa, N, Kaneda, K, Saito, Y, Ichihara, E and Morishita, K (2012). The increased expression of integrin a6 (ITGA6) enhances drug resistance in EVI1(high) leukemia. PLoS ONE 7: e30706.
179. Hu, S, Chen, R, Man, X, Feng, X, Cen, J, Gu, W et al. (2011). Function and expression of insulin-like growth factor-binding protein 7 (IGFBP7) gene in childhood acute myeloid leukemia. Pediatr Hematol Oncol 28: 279-287.
180. Nishioka, C, Ikezoe, T, Furihata, M, Yang, J, Serada, S, Naka, T et al. (2013). CD34?/CD38? acute myelogenous leukemia cells aberrantly express CD82 which regulates adhesion and survival of leukemia stem cells. Int J Cancer 132: 2006-2019.
181. Lu, L, Zhang, L, Xiao, Z, Lu, S, Yang, R and Han, ZC (2008). Neuropilin-1 in acute myeloid leukemia: expression and role in proliferation and migration of leukemia cells. Leuk Lymphoma 49: 331-338.
182. Miller, PG, Al-Shahrour, F, Hartwell, KA, Chu, LP, Järås, M, Puram, RV et al. (2013). In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell 24: 45-58.
183. Wang, C, Chen, Z, Li, Z and Cen, J (2010). The essential roles of matrix metalloproteinase-2, membrane type 1 metalloproteinase and tissue inhibitor of metalloproteinase-2 in the invasive capacity of acute monocytic leukemia SHI-1 cells. Leuk Res 34: 1083-1090.
184. Kornblau, SM, Qutub, A, Yao, H, York, H, Qiu, YH, Graber, D et al. (2013). Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38-stem-like cells. PLoS ONE 8: e78453.
185. Saito, Y, Kitamura, H, Hijikata, A, Tomizawa-Murasawa, M, Tanaka, S, Takagi, S et al. (2010). Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med 2: 17ra9.
186. Yoshimoto, G, Miyamoto, T, Jabbarzadeh-Tabrizi, S, Iino, T, Rocnik, JL, Kikushige, Y et al. (2009). FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 114: 5034-5043.
187. de Figueiredo-Pontes, LL, Pintão, MC, Oliveira, LC, Dalmazzo, LF, Jácomo, RH, Garcia, AB et al. (2008). Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. Cytometry B Clin Cytom 74: 163-168.
188. Feuring-Buske, M and Hogge, DE (2001). Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(-) progenitor cells from patients with acute myeloid leukemia. Blood 97: 3882-3889.
189. Jiang, X, Zhao, Y, Smith, C, Gasparetto, M, Turhan, A, Eaves, A et al. (2007). Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21: 926-935.
190. Jin, L, Hope, KJ, Zhai, Q, Smadja-Joffe, F and Dick, JE (2006). Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12: 1167-1174.
191. Mahon, FX, Réa, D, Guilhot, J, Guilhot, F, Huguet, F, Nicolini, F et al.; Intergroupe Français des Leucémies Myéloïdes Chroniques. (2010). Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11: 1029-1035.
192. Rousselot, P, Charbonnier, A, Cony-Makhoul, P, Agape, P, Nicolini, FE, Varet, B et al. (2014). Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 32: 424-430.
193. Jiang, X, Saw, KM, Eaves, A and Eaves, C (2007). Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 99: 680-693.
194. Chu, S, McDonald, T, Lin, A, Chakraborty, S, Huang, Q, Snyder, DS et al. (2011). Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 118: 5565-5572.
195. Jiang, X, Forrest, D, Nicolini, F, Turhan, A, Guilhot, J, Yip, C et al. (2010). Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood 116: 2112-2121.
196. Corbin, AS, Agarwal, A, Loriaux, M, Cortes, J, Deininger, MW and Druker, BJ (2011). Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 121: 396-409.
197. Hamilton, A, Helgason, GV, Schemionek, M, Zhang, B, Myssina, S, Allan, EK et al. (2012). Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119: 1501-1510.
198. Willyard, C (2013). Stem cells: bad seeds. Nature 498: S12-S13.
199. Copland, M (2009). Chronic myelogenous leukemia stem cells: What's new? Curr Hematol Malig Rep 4: 66-73.
200. Jin, L, Tabe, Y, Konoplev, S, Xu, Y, Leysath, CE, Lu, H et al. (2008). CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 7: 48-58.
201. Zhao, C, Blum, J, Chen, A, Kwon, HY, Jung, SH, Cook, JM et al. (2007). Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 12: 528-541.
202. Heidel, FH, Bullinger, L, Feng, Z, Wang, Z, Neff, TA, Stein, L et al. (2012). Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell 10: 412-424.
203. Helgason, GV, Karvela, M and Holyoake, TL (2011). Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood 118: 2035-2043.
204. Rothe, K, Lin, H, Lin, KB, Leung, A, Wang, HM, Malekesmaeili, M et al. (2014). The core autophagy protein ATG4B is a potential biomarker and therapeutic target in CML stem/progenitor cells. Blood 123: 3622-3634.
205. Zhou, LL, Zhao, Y, Ringrose, A, DeGeer, D, Kennah, E, Lin, AE et al. (2008). AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells. J Exp Med 205: 2657-2671.
206. Chen, M, Gallipoli, P, DeGeer, D, Sloma, I, Forrest, DL, Chan, M et al. (2013). Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex. J Natl Cancer Inst 105: 405-423.
207. Lin, H, Chen, M, Rothe, K, Lorenzi, MV, Woolfson, A and Jiang, X (2014). Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells. Oncotarget 5: 8637-8650.
208. Samanta, A, Perazzona, B, Chakraborty, S, Sun, X, Modi, H, Bhatia, R et al. (2011). Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia. Leukemia 25: 463-472.
209. Neviani, P, Harb, JG, Oaks, JJ, Santhanam, R, Walker, CJ, Ellis, JJ et al. (2013). PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 123: 4144-4157.
210. Higuchi, Y, Kawakami, S and Hashida, M (2010). Strategies for in vivo delivery of siRNAs: recent progress. BioDrugs 24: 195-205.
211. Ling, H, Fabbri, M and Calin, GA (2013). MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 12: 847-865.
212. Dürig, J, Dührsen, U, Klein-Hitpass, L, Worm, J, Hansen, JB, Ørum, H et al. (2011). The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia. Leukemia 25: 638-647.
213. Larsson, CA, Cote, G and Quintás-Cardama, A (2013). The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Mol Cancer Res 11: 815-827.
214. Notta, F, Mullighan, CG, Wang, JC, Poeppl, A, Doulatov, S, Phillips, LA et al. (2011). Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 469: 362-367.
215. Ding, L, Ley, TJ, Larson, DE, Miller, CA, Koboldt, DC, Welch, JS et al. (2012). Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481: 506-510.
216. Rushworth, SA and MacEwan, DJ (2008). HO-1 underlies resistance of AML cells to TNF-induced apoptosis. Blood 111: 3793-3801.
217. Rushworth, SA, Bowles, KM, Raninga, P and MacEwan, DJ (2010). NF-kappaB-inhibited acute myeloid leukemia cells are rescued from apoptosis by heme oxygenase-1 induction. Cancer Res 70: 2973-2983.
218. Fiskus, W, Pranpat, M, Balasis, M, Herger, B, Rao, R, Chinnaiyan, A et al. (2006). Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther 5: 3096-3104.
219. Despeaux, M, Chicanne, G, Rouer, E, De Toni-Costes, F, Bertrand, J, Mansat-De Mas, V et al. (2012). Focal adhesion kinase splice variants maintain primitive acute myeloid leukemia cells through altered Wnt signaling. Stem Cells 30: 1597-1610.
220. Voisset, E, Lopez, S, Chaix, A, Georges, C, Hanssens, K, Prébet, T et al. (2010). FES kinases are required for oncogenic FLT3 signaling. Leukemia 24: 721-728.
221. Dos Santos, C, Demur, C, Bardet, V, Prade-Houdellier, N, Payrastre, B and Récher, C (2008). A critical role for Lyn in acute myeloid leukemia. Blood 111: 2269-2279.
222. Wang, X, Gocek, E, Novik, V, Harrison, JS, Danilenko, M and Studzinski, GP (2010). Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D(3). Cell Cycle 9: 4542-4551.
223. Gao, SM, Xing, CY, Chen, CQ, Lin, SS, Dong, PH and Yu, FJ (2011). miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level. J Exp Clin Cancer Res 30: 110.
224. Fleischmann, KK, Pagel, P, Schmid, I and Roscher, AA (2014). RNAi-mediated silencing of MLL-AF9 reveals leukemia-associated downstream targets and processes. Mol Cancer 13: 27.
225. Spirin, PV, Nikitenko, NA, Lebedev, TD, Rubtsov, PM, Stocking, C and Prasolov, VS (2011). [Modulation of activated oncogene c-kit expression with RNA-interference]. Mol Biol (Mosk) 45: 1036-1045.
226. Gao, FH, Wu, YL, Zhao, M, Liu, CX, Wang, LS and Chen, GQ (2009). Protein kinase C-delta mediates down-regulation of heterogeneous nuclear ribonucleoprotein K protein: involvement in apoptosis induction. Exp Cell Res 315: 3250-3258.
227. Elmaagacli, AH, Koldehoff, M, Zakrzewski, JL, Steckel, NK, Ottinger, H and Beelen, DW (2007). Growth factor-independent 1B gene (GFI1B) is overexpressed in erythropoietic and megakaryocytic malignancies and increases their proliferation rate. Br J Haematol 136: 212-219.
228. Elmaagacli, AH, Koldehoff, M, Peceny, R, Klein-Hitpass, L, Ottinger, H, Beelen, DW et al. (2005). WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells. Haematologica 90: 326-334.
229. Karami, H, Baradaran, B, Esfahani, A, Sakhinia, M and Sakhinia, E (2014). Therapeutic Effects of Myeloid Cell Leukemia-1 siRNA on Human Acute Myeloid Leukemia Cells. Adv Pharm Bull 4: 243-248.
230. Pan, D, Li, Y, Li, Z, Wang, Y, Wang, P and Liang, Y (2012). Gli inhibitor GANT61 causes apoptosis in myeloid leukemia cells and acts in synergy with rapamycin. Leuk Res 36: 742-748.
231. Ptasznik, A, Nakata, Y, Kalota, A, Emerson, SG and Gewirtz, AM (2004). Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 10: 1187-1189.
232. Scherr, M, Battmer, K, Winkler, T, Heidenreich, O, Ganser, A and Eder, M (2003). Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood 101: 1566-1569.
233. Kaymaz, BT, Selvi, N, Gündüz, C, Aktan, C, Dalmizrak, A, Saydam, G et al. (2013). Repression of STAT3, S TAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K-562 with unmodified or chemically modified siRNAs and induction of apoptosis. Ann Hematol 92: 151-162.
234. Zhelev, Z, Bakalova, R, Ohba, H, Ewis, A, Ishikawa, M, Shinohara, Y et al. (2004). Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study). FEBS Lett 570: 195-204.
235. Aichberger, KJ, Mayerhofer, M, Krauth, MT, Skvara, H, Florian, S, Sonneck, K et al. (2005). Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 105: 3303-3311.
236. Gessner, A, Thomas, M, Castro, PG, Büchler, L, Scholz, A, Brümmendorf, TH et al. (2010). Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT. Leukemia 24: 1751-1759.
237. Wilda, M, Fuchs, U, Wössmann, W and Borkhardt, A (2002). Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene 21: 5716-5724.
238. Carvalho, G, Fabre, C, Braun, T, Grosjean, J, Ades, L, Agou, F et al. (2007). Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia. Oncogene 26: 2299-2307.
239. Braun, T, Carvalho, G, Coquelle, A, Vozenin, MC, Lepelley, P, Hirsch, F et al. (2006). NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 107: 1156-1165.
240. Yang, J, Ikezoe, T, Nishioka, C and Yokoyama, A (2013). A novel treatment strategy targeting shugoshin 1 in hematological malignancies. Leuk Res 37: 76-82.
241. Fernandez-Vidal, A, Ysebaert, L, Didier, C, Betous, R, De Toni, F, Prade-Houdellier, N et al. (2006). Cell adhesion regulates CDC25A expression and proliferation in acute myeloid leukemia. Cancer Res 66: 7128-7135.
242. Muranyi, AL, Dedhar, S and Hogge, DE (2010). Targeting integrin linked kinase and FMS-like tyrosine kinase-3 is cytotoxic to acute myeloid leukemia stem cells but spares normal progenitors. Leuk Res 34: 1358-1365.
243. Muranyi, AL, Dedhar, S and Hogge, DE (2009). Combined inhibition of integrin linked kinase and FMS-like tyrosine kinase 3 is cytotoxic to acute myeloid leukemia progenitor cells. Exp Hematol 37: 450-460.
244. Park, IK, Mishra, A, Chandler, J, Whitman, SP, Marcucci, G and Caligiuri, MA (2013). Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. Blood 121: 2064-2073.
245. Gu, TL, Mercher, T, Tyner, JW, Goss, VL, Walters, DK, Cornejo, MG et al. (2007). A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Blood 110: 323-333.
246. Walters, DK, Goss, VL, Stoffregen, EP, Gu, TL, Lee, K, Nardone, J et al. (2006). Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. Leuk Res 30: 1097-1104.
247. Walters, DK, Mercher, T, Gu, TL, O'Hare, T, Tyner, JW, Loriaux, M et al. (2006). Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 10: 65-75.
248. Okamoto, M, Hayakawa, F, Miyata, Y, Watamoto, K, Emi, N, Abe, A et al. (2007). Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD. Leukemia 21: 403-410.
249. Geletu, M, Balkhi, MY, Peer Zada, AA, Christopeit, M, Pulikkan, JA, Trivedi, AK et al. (2007). Target proteins of C/EBPalphap30 in AML: C/EBPalphap30 enhances sumoylation of C/EBPalphap42 via up-regulation of Ubc9. Blood 110: 3301-3309.
250. Walters, DK, Stoffregen, EP, Heinrich, MC, Deininger, MW and Druker, BJ (2005). RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518. Blood 105: 2952-2954.
251. Okuhashi, Y, Itoh, M, Nara, N and Tohda, S (2013). NOTCH knockdown affects the proliferation and mTOR signaling of leukemia cells. Anticancer Res 33: 4293-4298.
252. Yang, L, Yang, M, Zhang, H, Wang, Z, Yu, Y, Xie, M et al. (2012). S100A8-targeting siRNA enhances arsenic trioxide-induced myeloid leukemia cell death by down-regulating autophagy. Int J Mol Med 29: 65-72.
253. Wang, J, Li, W, Li, L, Yu, X, Jia, J and Chen, C (2011). CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol 33: 290-298.
254. Fernandes, MS, Reddy, MM, Croteau, NJ, Walz, C, Weisbach, H, Podar, K et al. (2010). Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem 285: 32596-32605.
255. Caligiuri, MA, Briesewitz, R, Yu, J, Wang, L, Wei, M, Arnoczky, KJ et al. (2007). Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood 110: 1022-1024.
256. Zhang, J, Tang, Y, Li, S, Liao, C and Guo, X (2010). Targeting of the B-lineage leukemia stem cells and their progeny with norcantharidin encapsulated liposomes modified with a novel CD19 monoclonal antibody 2E8 in vitro. J Drug Target 18: 675-687.
257. Chandran, P, Gupta, N, Retnakumari, AP, Malarvizhi, GL, Keechilat, P, Nair, S et al. (2013). Simultaneous inhibition of aberrant cancer kinome using rationally designed polymerprotein core-shell nanomedicine. Nanomedicine 9: 1317-1327.
258. Mao, Y, Wang, J, Zhao, Y, Wu, Y, Kwak, KJ, Chen, CS et al. (2014). A novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery. Nanomedicine 10: 393-400.
259. Yu, B, Mao, Y, Yuan, Y, Yue, C, Wang, X, Mo, X et al. (2013). Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells. Biomaterials 34: 6185-6193.
260. Mao, Y, Triantafillou, G, Hertlein, E, Towns, W, Stefanovski, M, Mo, X et al. (2013). Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies. Clin Cancer Res 19: 347-356.
261. Suh, W, Chung, JK, Park, SH and Kim, SW (2001). Anti-JL1 antibody-conjugated poly (L-lysine) for targeted gene delivery to leukemia T cells. J Control Release 72: 171-178.
262. Kovár, M, Strohalm, J, Etrych, T, Ulbrich, K and Ríhová, B (2002). Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect. Bioconjug Chem 13: 206-215.
263. Kovár, M, Mrkvan, T, Strohalm, J, Etrych, T, Ulbrich, K, Stastný, M et al. (2003). HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia. J Control Release 92: 315-330.
264. Phongpradist, R, Chittasupho, C, Okonogi, S, Siahaan, T, Anuchapreeda, S, Ampasavate, C et al. (2010). LFA-1 on leukemic cells as a target for therapy or drug delivery. Curr Pharm Des 16: 2321-2330.
265. Ai, J, Xu, Y, Li, D, Liu, Z and Wang, E (2012). Folic acid as delivery vehicles: targeting folate conjugated fluorescent nanoparticles to tumors imaging. Talanta 101: 32-37.